AvalonBay Communities, Inc., a member of the S&P 500, is an equity REIT that develops, redevelops, acquires and manages apartment communities in leading metropolitan areas in New England, the New York/New Jersey Metro area, the Mid-Atlantic, the Pacific Northwest, and Northern and Southern California, as well as in the Company's expansion regions of Raleigh-Durham and Charlotte, North Carolina, Southeast Florida, Dallas and Austin, Texas, and Denver, Colorado. As of December 31, 2024, the Company owned or held a direct or indirect ownership interest in 306 apartment communities containing 93,518 apartment homes in 12 states and the District of Columbia, of which 17 communities were under development.

AvalonBay Communities Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Climb Bio (CLYM) and ArriVent BioPharma, Inc. (AVBP)...

Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on ArriVent BioPharma, Inc. yesterday and set a price target of $42.00. According to Ti...

LifeSci Capital Remains a Buy on ArriVent BioPharma, Inc. (AVBP)

Morgan Stanley analyst Adam Kramer maintained a Hold rating on AvalonBay today and set a price target of $205.00. Kramer covers the Real Estate sec...

Morgan Stanley Reaffirms Their Hold Rating on AvalonBay (AVB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Harrow Health (HROW), Hims & Hers Health (HIMS) and ArriVent BioP...

Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Hims & Hers Health (HIMS) and ArriVent BioPharma, Inc. (AVBP)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on ArriVent BioPharma, Inc. today and set a price target of $44.00. According to TipRa...

H.C. Wainwright Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma, Inc. ( ($AVBP) ) has shared an update. On May 11, 2026, ArriVent BioPharma, Inc. filed a prospectus supplement with the U.S. Se...

ArriVent BioPharma Updates At-The-Market Equity Offering Program

Bank of America Securities analyst Jana Galan reiterated a Buy rating on AvalonBay today and set a price target of $213.00. Galan covers the Real E...

AvalonBay (AVB) Receives a Buy from Bank of America Securities

Companies in the Real Estate sector have received a lot of coverage today as analysts weigh in on AvalonBay (AVB), Ventas (VTR) and Public Storage ...

Analysts Offer Insights on Real Estate Companies: AvalonBay (AVB), Ventas (VTR) and Public Storage (PSA)

Evercore ISI analyst Steve Sakwa maintained a Hold rating on AvalonBay today and set a price target of $191.00. Sakwa covers the Real Estate sector...

Evercore ISI Remains a Hold on AvalonBay (AVB)

Colliers Securities analyst Barry Oxford maintained a Hold rating on AvalonBay yesterday and set a price target of $190.00. According to TipRanks, ...

Colliers Securities Remains a Hold on AvalonBay (AVB)

Avidbank Holdings ( ($AVBH) ) has issued an update. Avidbank Holdings, Inc. reported strong first‑quarter 2026 results on April 27, 2026, with net ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVB	$186.69	+0.85%	915.20K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVB	$186.69	+0.9%	915.20K
3
4
5
6

AVB

AVB

Get AvalonBay Communities Inc. Data in Excel

Get AvalonBay Communities Inc. Data in Excel